Publicación:
Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: A protocol of a META-epidemiological study

Página de artículo simple
dc.contributor.authorJimenez‑Mora, Mario A.
dc.contributor.authorRamírez-Varela, Andrea
dc.contributor.authorMeneses‑Echavez, Jose F.
dc.contributor.authorBidonde, Julia
dc.contributor.authorAngarita‑Fonseca, Adriana
dc.contributor.authorSiemieniuk, Reed A. C.
dc.contributor.authorZeraatkar, Dena
dc.contributor.authorBartoszko, Jessica J.
dc.contributor.authorBrignardello‑Petersen, Romina
dc.contributor.authorHonarmand, Kimia
dc.contributor.authorRochwerg, Bram
dc.contributor.authorGuyatt, Gordon
dc.contributor.authorYepes‑Nuñez, Juan José
dc.contributor.researchgroupFisioterapia Integralspa
dc.date.accessioned2022-03-10T19:11:12Z
dc.date.available2022-03-10T19:11:12Z
dc.date.issued2021-11-01
dc.descriptionDigitalspa
dc.description.abstractBackground: The coronavirus disease 19 (covid-19) pandemic has underscored the need to expedite clinical research, which may lead investigators to shift away from measuring patient-important outcomes (PIO), limiting research applicability. We aim to investigate if randomized controlled trials (RCTs) of covid-19 pharmacological thera‑ pies include PIOs. Methods: We will perform a meta-epidemiological study of RCTs that included people at risk for, or with suspected, probable, or confrmed covid-19, examining any pharmacological treatment or blood product aimed at prophylaxis or treatment. We will obtain data from all RCTs identifed in a living network metanalysis (NMA). The main data sources are the living WHO covid-19 database up to 1 March 2021 and six additional Chinese databases up to 20 February 2021. Two reviewers independently will review each citation, full-text article, and abstract data. To categorize the out‑ comes according to their importance to patients, we will adapt a previously defned hierarchy: a) mortality, b) quality of life/ functional status/symptoms, c) morbidity, and d) surrogate outcomes. Outcomes within the category a) and b) will be considered critically important to patients, and outcomes within the category c) will be regarded as important. We will use descriptive statistics to assess the proportion of studies that report each category of outcomes. We will perform univariable and multivariable analysis to explore associations between trial characteristics and the likelihood of reporting PIOs. Discussion: The fndings from this meta-epidemiological study will help health care professionals and researchers understand if the current covid-19 trials are efectively assessing and reporting the outcomes that are important to patients. If a defciency in capturing PIOs is identifed, this information may help inform the development of future RCTs in covid-19. Systematic review registrations: Open Science Framework registration: osf.io/6xgjz.spa
dc.description.researchareaCiencias Médicas y de la Saludspa
dc.format.extent6 pspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1186/s13643-021-01838-8
dc.identifier.urihttps://repositorio.udes.edu.co/handle/001/6307
dc.language.isoengspa
dc.publisher.placeReino Unidospa
dc.relation.citationendpage6spa
dc.relation.citationissue289spa
dc.relation.citationstartpage1spa
dc.relation.citationvolume10spa
dc.relation.citesJimenez-Mora, M.A., Varela, A.R., Meneses-Echavez, J.F. et al. Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study. Syst Rev 10, 289 (2021). https://doi.org/10.1186/s13643-021-01838-8
dc.relation.indexedScopusspa
dc.relation.ispartofjournalSystematic Reviewsspa
dc.rights© The Author(s) 2021.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución 4.0 Internacional (CC BY 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/spa
dc.sourcehttps://systematicreviewsjournal.biomedcentral.com/track/pdf/10.1186/s13643-021-01838-8.pdfspa
dc.subject.proposalPatient-important outcomeeng
dc.subject.proposalReportingeng
dc.subject.proposalTreatmenteng
dc.subject.proposalPreventioneng
dc.subject.proposalCoronaviruseng
dc.subject.proposalCovid-19eng
dc.titlePatient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: A protocol of a META-epidemiological studyspa
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dcterms.audienceTodas las Audienciasspa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
Archivos
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
Nombre:
Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19. A protocol of a META-epidemiological study.pdf
Tamaño:
234.24 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Paquete de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
59 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
AGBFA. Artículos de Investigación